Treatments for EBV-linked non-Hodgkin lymphoma
Therapy for Non-Hodgkin lympoma
['FUNDING_R01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11161642
New treatments aimed at Epstein-Barr virus–linked non-Hodgkin lymphoma for people living with HIV.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11161642 on ClinicalTrials.gov |
What this research studies
This project focuses on how Epstein-Barr virus (EBV) contributes to several aggressive non-Hodgkin lymphomas, especially in people with HIV. Researchers will study tumor cells and patient-derived samples to identify the biological mechanisms that drive growth and chemotherapy resistance. They will use those findings to test targeted approaches in laboratory models and patient-related specimens with the goal of finding therapies that overcome resistance. The work is coordinated at UNC Chapel Hill and could lead to future clinical testing.
Who could benefit from this research
Good fit: People with EBV-positive non-Hodgkin lymphoma — such as NK/T-cell lymphoma, Burkitt lymphoma, or EBV-positive diffuse large B-cell lymphoma — and especially individuals living with HIV are the most relevant candidates.
Not a fit: Patients whose lymphomas are EBV-negative or who have unrelated cancers would be unlikely to benefit directly from this specific research.
Why it matters
Potential benefit: If successful, this research could produce new targeted treatments that improve outcomes and survival for people with EBV-associated non-Hodgkin lymphoma, particularly those living with HIV.
How similar studies have performed: Some laboratory and early clinical efforts targeting EBV-driven pathways have shown promise, but broadly effective therapies for aggressive EBV-associated NHL are still limited.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DAMANIA, BLOSSOM A — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: DAMANIA, BLOSSOM A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus